Astellas acquisition of Xyphos : Japanese pharma company Astellas Pharma has acquired US biotech company Xyphos Biosciences in a deal worth up to $665 million as per the latest pharma acquisition news. The acquisition of Xyphos Biosciences gives Astellas Pharma access to the former’s ACCEL technology platform alongside its immuno-oncology talent to develop new and […]
Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes Therapeutics in an all-cash deal worth about $3 billion, as per pharma acquisition news. Based in California, Audentes Therapeutics calls itself a clinical-stage company focused on developing a portfolio of Adeno-associated virus (AAV)-based genetic medicines for the […]
Japanese pharmaceutical giant Astellas Pharma has announced the acquisition of US-based Potenza Therapeutics in a significant transaction valued at up to $404.7 million. This strategic move is the culmination of a collaborative partnership established between the two companies in 2015, aimed at advancing novel immuno-oncology (IO) therapies. Under the terms of the acquisition, Astellas has […]